CYP2C9 and hemorrhage: Increased levels of unbound Warfarin could result and could increase the risk of hemorrhage.” Take another example between Warfarin and Ivacaftor54, conducts a DDI study and reports that “caution and appropriate monitoring are recommended when concomitant substrates of CYP2C9, CYP3A and/or P-gp are used during treatment with Ivacaftor, particularly drugs with a narrow therapeutic index, such as Warfarin.” Finally, we provide the top 10 outputs for DTI, PPI, and GDI tasks in Appendix 3.